Chas­ing Am­gen on KRAS com­bo, Roche dish­es out $75M for Re­lay's SHP2 drug to pair with in-house pro­gram

With Am­gen’s KRAS drug poised to cross the fin­ish line, it’s no longer enough for its Big Phar­ma brethren to just have their own KRAS plays. On Mon­day Roche be­came the lat­est to fol­low the fron­trun­ner in adopt­ing a com­bo strat­e­gy, tap­ping Re­lay Ther­a­peu­tics for a SHP2 pro­gram it can pair with an in-house KRAS G12C drug.

In ad­di­tion to $75 mil­lion up­front, Re­lay al­so ex­pects to bag $25 mil­lion in the near term. The amount of biobucks on the ta­ble de­pends on whether it opts for a 50/50 prof­it/cost share for RLY-1971, which is cur­rent­ly still in Phase I: If it does, the mile­stones are capped at $410 mil­lion as it would be el­i­gi­ble for half of the prof­its from US sales. But oth­er­wise, the mile­stones could add up to $695 mil­lion plus roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER